IL6 and inflammation: It is also expected that curtailing the establishment of pancreatic inflammation by reducing the intra-pancreatic production of IL-6, CXCL1, and MCP-1, would lead to significantly reduced T-cell proliferation and chemotaxis (52), recruitment of neutrophils (53), and macrophages, respectively.